CollPlant Biotechnologies (CLGN) Registration Filing summary

Company overview and business model

• Focuses on regenerative and aesthetic medicine, leveraging proprietary recombinant human collagen (rhCollagen) produced in genetically engineered tobacco plants for medical aesthetics and 3D bioprinting of tissues and organs.

• Key products include dermal and soft tissue fillers (in partnership with AbbVie), photocurable dermal fillers, and 3D-bioprinted breast implants targeting the $3 billion global breast implant market.

• Commercially launched rhCollagen-based bioink products (Collink.3D series) for scalable 3D-bioprinting applications in regenerative medicine.

• Utilizes plant-based technology to avoid animal-derived collagen, promoting sustainability and ethical practices.

Financial performance and metrics

• Cash and cash equivalents as of September 30, 2025: $8.5 million; total shareholders' equity: $9.3 million.

• Aggregate market value of outstanding equity held by non-affiliates as of January 7, 2026: approximately $20 million.

• Sold securities with an aggregate market value of $3.6 million in the prior 12 months (excluding this offering).

• Expects to continue incurring losses and negative cash flows until products reach commercial profitability; current resources insufficient for the next 12 months.

Use of proceeds and capital allocation

• Net proceeds intended for funding research and development, working capital, and general corporate purposes.

• Specific allocation and timing of proceeds will depend on funding requirements and availability of other funds.